Enhanced antibacterial activity of rifampicin associated with biodegradable polybutylcyanoacrylate nanoparticles

I. N. Skidan, S. E. Gelperina, S. E. Severin, A. E. Gulyaev

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Association of rifampicin with polybutylcyanoacrylate nanoparticles provided considerable enhancement of drug antibacterial activity. In vitro nanoparticle-loaded rifampicin was more active against Staphylococcus aureus and Mycobacterium avium, localized in isolated alveolar macrophages. Level of rifampicin in macrophages increased 2-3-fold after incubation with rifampicin-loaded nanoparticles comparing to the free drug. High therapeutic efficacy of colloidal rifampicin was demonstrated in vivo. Use of nanoparticles provided 2-fold increase in rifampicin efficacy, comparing with the free drug at treatment of staphylococcus sepsis in mice. Single administration of nanoparticulate rifampicin in the dose 25 mg/kg resulted in 80% survival of mice with salmonellosis, while 50 mg/kg of free rifampicin could provide only 10% survival. It may be considered that high antibacterial efficacy of rifampicin bound to nanoparticles is due to its effective delivery to macrophages.

Original languageEnglish
Pages (from-to)23-26
Number of pages4
JournalAntibiotiki i Khimioterapiya
Volume48
Issue number1
Publication statusPublished - 2003
Externally publishedYes

Fingerprint

Rifampin
Nanoparticles
Macrophages
Pharmaceutical Preparations
Mycobacterium avium
Salmonella Infections
Alveolar Macrophages
Staphylococcus
Staphylococcus aureus
Sepsis

Keywords

  • Alveolar macrophages
  • Antibacterial activity
  • Nanoparticles
  • Rifampicin

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology

Cite this

Enhanced antibacterial activity of rifampicin associated with biodegradable polybutylcyanoacrylate nanoparticles. / Skidan, I. N.; Gelperina, S. E.; Severin, S. E.; Gulyaev, A. E.

In: Antibiotiki i Khimioterapiya, Vol. 48, No. 1, 2003, p. 23-26.

Research output: Contribution to journalArticle

@article{0347fb6f08ca422a887981c3156ac64a,
title = "Enhanced antibacterial activity of rifampicin associated with biodegradable polybutylcyanoacrylate nanoparticles",
abstract = "Association of rifampicin with polybutylcyanoacrylate nanoparticles provided considerable enhancement of drug antibacterial activity. In vitro nanoparticle-loaded rifampicin was more active against Staphylococcus aureus and Mycobacterium avium, localized in isolated alveolar macrophages. Level of rifampicin in macrophages increased 2-3-fold after incubation with rifampicin-loaded nanoparticles comparing to the free drug. High therapeutic efficacy of colloidal rifampicin was demonstrated in vivo. Use of nanoparticles provided 2-fold increase in rifampicin efficacy, comparing with the free drug at treatment of staphylococcus sepsis in mice. Single administration of nanoparticulate rifampicin in the dose 25 mg/kg resulted in 80{\%} survival of mice with salmonellosis, while 50 mg/kg of free rifampicin could provide only 10{\%} survival. It may be considered that high antibacterial efficacy of rifampicin bound to nanoparticles is due to its effective delivery to macrophages.",
keywords = "Alveolar macrophages, Antibacterial activity, Nanoparticles, Rifampicin",
author = "Skidan, {I. N.} and Gelperina, {S. E.} and Severin, {S. E.} and Gulyaev, {A. E.}",
year = "2003",
language = "English",
volume = "48",
pages = "23--26",
journal = "Antibiotiki i Khimioterapiya",
issn = "0235-2990",
publisher = "Media Sfera",
number = "1",

}

TY - JOUR

T1 - Enhanced antibacterial activity of rifampicin associated with biodegradable polybutylcyanoacrylate nanoparticles

AU - Skidan, I. N.

AU - Gelperina, S. E.

AU - Severin, S. E.

AU - Gulyaev, A. E.

PY - 2003

Y1 - 2003

N2 - Association of rifampicin with polybutylcyanoacrylate nanoparticles provided considerable enhancement of drug antibacterial activity. In vitro nanoparticle-loaded rifampicin was more active against Staphylococcus aureus and Mycobacterium avium, localized in isolated alveolar macrophages. Level of rifampicin in macrophages increased 2-3-fold after incubation with rifampicin-loaded nanoparticles comparing to the free drug. High therapeutic efficacy of colloidal rifampicin was demonstrated in vivo. Use of nanoparticles provided 2-fold increase in rifampicin efficacy, comparing with the free drug at treatment of staphylococcus sepsis in mice. Single administration of nanoparticulate rifampicin in the dose 25 mg/kg resulted in 80% survival of mice with salmonellosis, while 50 mg/kg of free rifampicin could provide only 10% survival. It may be considered that high antibacterial efficacy of rifampicin bound to nanoparticles is due to its effective delivery to macrophages.

AB - Association of rifampicin with polybutylcyanoacrylate nanoparticles provided considerable enhancement of drug antibacterial activity. In vitro nanoparticle-loaded rifampicin was more active against Staphylococcus aureus and Mycobacterium avium, localized in isolated alveolar macrophages. Level of rifampicin in macrophages increased 2-3-fold after incubation with rifampicin-loaded nanoparticles comparing to the free drug. High therapeutic efficacy of colloidal rifampicin was demonstrated in vivo. Use of nanoparticles provided 2-fold increase in rifampicin efficacy, comparing with the free drug at treatment of staphylococcus sepsis in mice. Single administration of nanoparticulate rifampicin in the dose 25 mg/kg resulted in 80% survival of mice with salmonellosis, while 50 mg/kg of free rifampicin could provide only 10% survival. It may be considered that high antibacterial efficacy of rifampicin bound to nanoparticles is due to its effective delivery to macrophages.

KW - Alveolar macrophages

KW - Antibacterial activity

KW - Nanoparticles

KW - Rifampicin

UR - http://www.scopus.com/inward/record.url?scp=0037968388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037968388&partnerID=8YFLogxK

M3 - Article

C2 - 12741319

AN - SCOPUS:0037968388

VL - 48

SP - 23

EP - 26

JO - Antibiotiki i Khimioterapiya

JF - Antibiotiki i Khimioterapiya

SN - 0235-2990

IS - 1

ER -